NCT06625047: Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy |
|
|
| Recruiting | 4 | 30 | US | Assessment, Assess, Study Assessment, Study Observation, Questionnaire Administration, Telemedicine Visit, Telemedicine Encounter, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ | Mayo Clinic | Astrocytoma, IDH-Mutant, Glioblastoma, Glioma, Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted | 03/25 | 03/25 | | |
NCT03532295: Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas |
|
|
| Active, not recruiting | 2 | 51 | US | Epacadostat, Bevacizumab, Avastin, Radiation therapy, Peripheral blood draw, Retifanlimab, INCMGA00012 | Washington University School of Medicine, Incyte Corporation | Glioma, Glioblastoma | 07/24 | 04/26 | | |
NCT06377696: Remote Cognitive Assessment and Wearable Device While Assessing the Impact of Metformin in Patients with History of Cranial Radiation Therapy |
|
|
| Recruiting | 2 | 100 | US | Best Practice, standard of care, standard therapy, Medical Device Usage and Evaluation, Metformin, N,N-dimethylbiguanide, Neurocognitive Assessment, Questionnaire Administration | Mayo Clinic | Malignant Brain Neoplasm | 05/27 | 05/27 | | |
